Synovial Sarcoma of the Hyoid Bone: A Rare Case

A case report by Ryan Toledo, Jennifer Khong, and colleagues (published August 31, 2026; DOI: 10.7812/TPP/26.039) describes only the third known synovial sarcoma arising from the hyoid bone, a small U-shaped bone in the neck. The patient, a 62-year-old man, remains disease-free years after treatment.

The Case

The patient had a slowly growing left-sided neck mass with no swallowing problems, voice changes, or systemic symptoms. Imaging showed a 4 to 5 cm mass at the back of the left hyoid bone, with no spread on PET/CT. Because it looked like more common neck masses, diagnosis depended on a core needle biopsy, which found a spindle cell tumor with the t(X;18) translocation and SS18-SSX fusion protein. It was staged T3N0M0.

After a tumor board review, he received four cycles of doxorubicin, ifosfamide, and mesna (AIM), then surgery with a left neck dissection. Pathology found no viable tumor (a complete pathologic response). Radiation followed, and he has had no recurrence on surveillance imaging.

How It Compares

The two earlier hyoid cases had poorer or unknown outcomes. An 11-year-old girl had surgery alone with no reported follow-up. A 16-year-old boy received surgery and radiation, with chemotherapy delayed, and died of metastatic disease at 37 months. The authors suggest that starting chemotherapy first may better control microscopic spread and make clean surgical margins easier to achieve.

Why It Matters

Only about 5% of synovial sarcomas occur in the head and neck, where tight anatomy makes complete removal difficult. Key takeaways:

• Consider sarcoma in atypical neck masses, since delayed diagnosis is common.
• Molecular confirmation is essential when imaging and location are unusual.
• Multidisciplinary planning matters for sequencing chemotherapy, surgery, and radiation.

Caveat: This is a single patient, so it cannot prove the treatment sequence caused the outcome, and the benefit of chemotherapy in localized synovial sarcoma remains debated.

Ask for Biomarker Testing – It Opens Doors to Targeted Care

Biomarker testing doesn’t only confirm diagnosis – it determines what treatments you can access. If you or a loved one has synovial sarcoma, ask your care team whether these tests have been completed:

• HLA typing – a blood test checking immune markers required for cell therapies like Tecelra, an FDA-approved personalized therapy using your own immune cells to target cancer.
• MAGE-A4 testing – a tumor test required for Tecelra eligibility and related therapies.
• NY-ESO-1 testing – a tumor test that may qualify you for clinical trials or emerging treatments like lete-cel.

If these haven’t been ordered, request them now. National labs including Caris Life Sciences and Tempus specialize in sarcoma profiling. For printable resources to share with your care team, visit www.sarcomabiomarkertesting.com.

For more information, read the original publication. For more information about the Synovial Sarcoma Foundation, please visit our website.

SEO Keywords

synovial sarcoma of the hyoid bone, hyoid bone tumor, head and neck synovial sarcoma, synovial sarcoma case report, rare neck mass diagnosis, neoadjuvant chemotherapy synovial sarcoma, doxorubicin ifosfamide synovial sarcoma, AIM chemotherapy regimen, trimodality therapy sarcoma, soft tissue sarcoma head and neck, complete pathologic response sarcoma, SS18-SSX fusion, t(X;18) translocation, synovial sarcoma diagnosis, synovial sarcoma biomarker testing, HLA typing sarcoma, MAGE-A4 testing, NY-ESO-1 testing, Tecelra synovial sarcoma, lete-cel, sarcoma cell therapy, sarcoma tumor profiling, Synovial Sarcoma Foundation